ambrisentan NDC 50090-7670

NDC codes

FDA NDC Directory

Product NDC (as listed)50090-7670Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50090-7670Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50090-7670-0	50090767000	30 TABLET, FILM COATED in 1 BOTTLE (50090-7670-0)Marketed from Oct 7, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): ambrisentan
Generic name (nonproprietary): ambrisentan
Active ingredients: Ambrisentan — 10 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: A-S Medication Solutions
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 216531
Marketing start: Jul 21, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Endothelin Receptor Antagonists (Mechanism)
Identifiers: Product ID 50090-7670_0a07dd73-2271-409b-a0b4-de0db982250eSPL ID 0a07dd73-2271-409b-a0b4-de0db982250eSPL set ID a7dcdea4-d3da-4dc1-9193-6ebdb5b4e690RxCUI 722116UNII HW6NV07QEC
Pharmacologic class: Endothelin Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450090767000 followed by a unit qualifier and the quantity

Package 50090-7670-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 8, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Ambrisentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II to III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%). Ambrisentan is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included trials predominantly in patients with WHO …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 216531

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 216531
Product	Strength	Form · route	Labeler	Product NDC
ambrisentan	Ambrisentan 5 mg/1	Tablet, Film coatedOral	A-S Medication Solutions	50090-7671
ambrisentan	Ambrisentan 5 mg/1	Tablet, Film coatedOral	Aurobindo Pharma Limited	59651-494
ambrisentan	Ambrisentan 10 mg/1	Tablet, Film coatedOral	Aurobindo Pharma Limited	59651-495